ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL

American Journal of Clinical Pathology

Volumn 122, Issue 4, 2004, Pages 582-587

  Sup, Stephen J ^a   Domiati Saad, Rana ^b   Kelley, Todd W ^a   Steinle, Roxanne ^a   Zhao, Xinyu ^a   Hsi, Eric D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Immunohistochemistry; Leukemia; Lymphoma; Small lymphocytic lymphoma; ZAP 70

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70; PROTEIN TYROSINE KINASE; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; GENE MUTATION; HEMATOPOIETIC SYSTEM TUMOR; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOCYTOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL LYMPHOCYTIC LYMPHOMA; WESTERN BLOTTING;

EID: 4644224460     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/WVQPVDF8UF7AV21X     Document Type: Article

References (20)

1. Chan AC, Iwashima M, Turck CW, et al. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell. 1992;71:649-662.
2. Kadlecek TA, van Oers NS, Lefrancois L, et al. Differential requirements for ZAP-70 in TCR signaling and T cell development. J Immunol. 1998;161:4688-4694.
3. van Oers NS, Killeen N, Weiss A. Lck regulates the tyrosine phosphorytation of the T cell receptor subunits and ZAP-70 in murine thymocytes. J Exp Med. 1996;183:1053-1062.
4. Zhang W, Sloan-Lancaster J, Kitchen J, et al. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell. 1998;92:83-92.
5. Sloan-Lancaster J, Zhang W, Presley J, et al. Regulation of ZAP-70 intracellular localization: visualization with the green fluorescent protein. J Exp Med. 1997;186:1713-1724.
6. Sloan-Lancaster J, Steinberg TH, Allen PM. Selective loss of the calcium ion signaling pathway in T cells maturing toward a T helper 2 phenotype. J Immunol. 1997;159:1160-1168.
7. Zhang W, Samelson LE. The role of membrane-associated adaptors in T cell receptor signalling. Semin Immunol. 2000;12:35-41.
8. Elder ME. SCID due to ZAP-70 deficiency. J Pediatr Hematol Oncol. 1997;19:546-550.
9. Elder ME, Lin D, Clever J, et al. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science. 1994;264:1596-1599.
10. Schweighoffer E, Vanes L, Mathiot A, et al. Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity. 2003;18:523-533.
11. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
12. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944-4951.
13. Wang X, Stollar BD. Human immunoglobulin variable region gene analysis by single cell RT-PCR. J Immunol Methods. 2000;244:217-225.
14. Trainor KJ, Brisco MJ, Wan JH, et al. Gene rearrangement in B- and T-lymphoproliferative disease detected by the polymerase chain reaction. Blood. 1991;78:192-196.
15. H) somatic hypermutation (SHM) and prognostic determination in chronic lymphocytic leukemia (CLL) [abstract]. Mod Pathol. 2004;17:268A.
16. Cheng AM, Rowley B, Pao W, et al. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 1995;378:303-306.
17. Turner M, Mee PJ, Costello PS, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature. 1995;378:298-302.
18. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100:4609-4614.
19. H genes and the frequency of somatic mutations. Blood. 2003;101:4042-4046.
20. H mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood. 2003;102:3003-3009.